Super-antigen fusion proteins and the use thereof
AssigneeHealthbanks Biotech Co., Ltd.
InventorsHsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment encoding a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid of the peptide fragment encoding the partial SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The present invention further relates to DNA sequences encoding the partial SARS E2 spike protein includes SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, or SEQ ID NO.8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.
Claims16
A super-antigen fusion protein comprising:
- (a) a peptide fragment encoding at least a partial severe acute respiratory syndrome (SARS) E2 spike protein;
- and
- (b) a translocating peptide;
- wherein the amino acid of said peptide fragment encoding SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, or SEQ ID NO.4.
A nucleic acid sequence, which expresses specific SARS E2 spike protein in an E. Coli expression system, comprising the following sequence:
- SEQ ID NO.5;
- SEQ ID NO.6;
- SEQ ID NO.7;
- or
- SEQ ID NO.8.
A peptide for binding to T lymphocyte, comprising a peptide fragment encoding at least partial SARS E2 spike protein, and the amino acid sequence of said peptide is:
- SEQ ID NO.1;
- SEQ ID NO.2;
- SEQ ID NO.3;
- or
- *SEQ ID NO.4.
A pharmaceutical composition for a peptide binding to a T lymphocyte, comprising a peptide fragment encoding at least a partial SARS E2 spike protein;
- wherein the amino acid sequence of said peptide fragment encoding SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, or SEQ ID NO.4.
Dependencies are inferred from the claim text.